查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574815

二異丙胺市場：按應用、最終用戶、劑型、分銷管道、治療領域分類 - 全球預測 2025-2030

Diisopromine Market by Application (Medical Treatments, Pharmaceuticals, Research & Development), End User (Clinics, Hospitals, Research Institutes), Drug Form, Distribution Channel, Therapeutic Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年二異丙胺市值為2.1328億美元，預計到2024年將達到2.2387億美元，複合年成長率為5.84%，預計到2030年將達到3.1749億美元。

二異丙胺是一種解痙劑，主要是因為它可以緩解平滑肌痙攣並促進血流改善，特別是在周邊血管疾病中。對二異丙胺的需求源於其獨特的非麻醉特性，使其成為解決血管和肌肉併發症的鴉片類藥物治療的更安全替代品。其應用擴展到周邊動脈疾病等慢性疾病的管理和增強循環功能，特別是在老年族群。最終用途範圍主要圍繞製藥業和醫療機構，旨在改善心血管疾病的治療。二異丙胺市場的成長主要受到血管疾病盛行率的增加、老年人口的擴大以及藥物化學的進步改善了給藥機制的影響。新興經濟體存在著巨大的市場機會，這些經濟體的醫療基礎設施正在迅速開拓，人們對血管疾病的認知和診斷也不斷提高。希望利用這些機會的公司應該投資臨床試驗，探索潛在的新應用，並探索與當地醫療保健提供者建立合資企業，以提高市場滲透率。

主要市場統計
基準年[2023] 21328萬美元
預測年份 [2024] 2.2387億美元
預測年份 [2030] 31749萬美元
複合年成長率（%） 5.84%

然而，挑戰仍然存在，例如嚴格的監管核准可能會延遲市場進入，以及更實惠或成熟的替代品的可用性可能會限制二異丙胺的採用。人們也擔心副作用和藥物交互作用，需要徹底調查以確保患者安全。在創新方面，針對患者的製劑和給藥系統（例如緩釋片和注射劑）的研究至關重要。此外，探索這種化合物在治療其他平滑肌相關疾病方面的潛力，並整合數位健康技術以實現更好的治療管理，為業務成長提供了一個有希望的途徑。整體而言，景觀市場的特徵是機會與挑戰並存，需要策略規劃與適應能力，才能在競爭格局中取得成功。

市場動態：揭示快速發展的二異丙胺市場的關鍵市場洞察

二異丙胺市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 提高醫療保健專業人員對二異丙胺益處的認知
    • 嚴格的品質和安全標準推動了對二異丙胺的需求
    • 二異丙胺與替代療法相比的成本效益
    • 老年人口增加，易患胃腸道疾病及慢性病
  • 市場限制因素
    • 限制二異丙胺廣泛使用的物理和化學特性
  • 市場機會
    • 二異丙胺在利基條件和罕見疾病的新治療應用
    • 擴大二異丙胺在精準醫療標靶給藥系統中的使用
    • 創新的疼痛管理解決方案帶來二異丙胺市場成長潛力
  • 市場挑戰
    • 影響二異丙胺可用性的分銷管道限制

波特的五力：駕馭二異丙胺市場的策略工具

波特的五力架構是了解二異丙胺市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對二異丙胺市場的外部影響

外部宏觀環境因素在塑造二異丙胺市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解二異丙胺市場的競爭狀況

二異丙胺市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣二異丙胺市場供應商的績效評估

FPNV定位矩陣是評估二異丙胺市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了二異丙胺市場的成功之路

二異丙胺市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高醫護人員對二異丙胺益處的認知
      • 嚴格的品質和安全標準推動了對二異丙胺的需求
      • 二異丙胺與替代治療方法相比的成本效益
      • 越來越多的老年人口更容易患胃腸道和慢性疾病
    • 抑制因素
      • 限制二異丙胺廣泛使用的物理和化學特性
    • 機會
      • 二異丙胺在利基條件和罕見疾病的新治療應用
      • 擴大二異丙胺在精準醫療標靶給藥系統的應用
      • 創新的疼痛管理解決方案帶來二異丙胺市場成長潛力
    • 任務
      • 影響二異丙胺可用性的分銷管道限制
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章二異丙胺市場：依應用分類

  • 醫療
    • 慢性疼痛管理
    • 神經病變的治療
  • 藥品
    • 非處方藥
    • 處方藥
  • 研究與開發
    • 醫學研究
    • 藥物研究

第7章二異丙胺市場：依最終用戶分類

  • 診所
    • 普通科診所
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 調查機構

第8章以劑型分類的二異丙胺市場

  • 膠囊
  • 注射
  • 藥片

第9章二異丙胺市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章依治療領域分類的二異丙胺市場

  • 胃腸病學
    • 膽管痙攣
    • 大腸激躁症
  • 神經病學
    • 中樞性疼痛症候群
    • 周邊神經神經病變
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛

第11章美洲二異丙胺市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區二異丙胺市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲二異丙胺市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C62918895

The Diisopromine Market was valued at USD 213.28 million in 2023, expected to reach USD 223.87 million in 2024, and is projected to grow at a CAGR of 5.84%, to USD 317.49 million by 2030.

Diisopromine is an antispasmodic agent primarily employed for its potential to relieve smooth muscle spasms and facilitate improved blood flow, particularly in peripheral vascular disorders. The necessity for diisopromine arises from its distinct non-narcotic properties, making it a safer alternative to opioid-based treatments for addressing vascular and muscular complications. Its applications extend to managing chronic conditions like peripheral artery disease and enhancing circulatory functions, especially in aging demographics. The end-use scope mostly revolves around the pharmaceutical industry and healthcare institutions, aiming to improve treatments for cardiovascular ailments. Growth in the diisopromine market is chiefly influenced by the increasing prevalence of vascular diseases, expanding geriatric population, and advancements in medicinal chemistry that allow for improved delivery mechanisms. Significant market opportunities lie in emerging economies where healthcare infrastructure is undergoing rapid development, and there is increased awareness and diagnosis of vascular conditions. Companies aiming to capitalize on these opportunities should invest in clinical trials to research potential new applications and explore collaborative ventures with local healthcare providers to enhance market penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 213.28 million
Estimated Year [2024] USD 223.87 million
Forecast Year [2030] USD 317.49 million
CAGR (%) 5.84%

However, challenges persist, including stringent regulatory approvals that may delay market entry and the availability of more affordable or established alternatives which might limit diisopromine's adoption. There are also concerns about possible side effects and drug interactions, which require thorough investigations to ensure patient safety. In terms of innovation, research focusing on patient-targeted formulations and delivery systems like slow-release tablets or injectables could be pivotal. Additionally, exploring the compound's potential in treating other smooth muscle-related conditions and integrating digital health technologies for better treatment management offers promising avenues for business growth. Overall, the diisopromine market is characterized by a balanced mix of opportunity and challenge, demanding strategic planning and adaptability to thrive in a competitive landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diisopromine Market

The Diisopromine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing awareness among healthcare professionals about the benefits of diisopromine
    • Stringent quality and safety standards driving the demand for diisopromine
    • Cost-effectiveness of diisopromine as compared to alternative treatments
    • Rising geriatric population prone to gastrointestinal and chronic conditions
  • Market Restraints
    • Physical and chemical properties limiting the widespread use of Diisopromine
  • Market Opportunities
    • Emerging therapeutic uses of diisopromine for niche medical conditions and rare diseases
    • Expanding diisopromine applications in targeted drug delivery systems for precision medicine
    • Potential growth in the diisopromine market through innovative pain management solutions
  • Market Challenges
    • Limitations in distribution channels affecting Diisopromine availability

Porter's Five Forces: A Strategic Tool for Navigating the Diisopromine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diisopromine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diisopromine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diisopromine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diisopromine Market

A detailed market share analysis in the Diisopromine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diisopromine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diisopromine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diisopromine Market

A strategic analysis of the Diisopromine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diisopromine Market, highlighting leading vendors and their innovative profiles. These include Arkema S.A., Asahi Kasei Corporation, BASF SE, Celanese Corporation, Clariant AG, Dow Chemical Company, DuPont de Nemours, Inc., Eastman Chemical Company, Evonik Industries AG, Honeywell International Inc., Huntsman Corporation, Lanxess AG, LG Chem Ltd., LyondellBasell Industries N.V., Mitsui Chemicals, Inc., Solvay S.A., Sumitomo Chemical Company, Limited, Toray Industries, Inc., Tosoh Corporation, and Wacker Chemie AG.

Market Segmentation & Coverage

This research report categorizes the Diisopromine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Application, market is studied across Medical Treatments, Pharmaceuticals, and Research & Development. The Medical Treatments is further studied across Chronic Pain Management and Neuropathy Treatment. The Pharmaceuticals is further studied across Over-The-Counter Drugs and Prescription Drugs. The Research & Development is further studied across Medical Studies and Pharmaceutical Research.
  • Based on End User, market is studied across Clinics, Hospitals, and Research Institutes. The Clinics is further studied across General Clinics and Specialty Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Drug Form, market is studied across Capsules, Injectables, and Tablets.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Therapeutic Area, market is studied across Gastroenterology, Neurology, and Pain Management. The Gastroenterology is further studied across Biliary Spasm and Irritable Bowel Syndrome. The Neurology is further studied across Central Pain Syndromes and Peripheral Neuropathy. The Pain Management is further studied across Acute Pain and Chronic Pain.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness among healthcare professionals about the benefits of diisopromine
      • 5.1.1.2. Stringent quality and safety standards driving the demand for diisopromine
      • 5.1.1.3. Cost-effectiveness of diisopromine as compared to alternative treatments
      • 5.1.1.4. Rising geriatric population prone to gastrointestinal and chronic conditions
    • 5.1.2. Restraints
      • 5.1.2.1. Physical and chemical properties limiting the widespread use of Diisopromine
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging therapeutic uses of diisopromine for niche medical conditions and rare diseases
      • 5.1.3.2. Expanding diisopromine applications in targeted drug delivery systems for precision medicine
      • 5.1.3.3. Potential growth in the diisopromine market through innovative pain management solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations in distribution channels affecting Diisopromine availability
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diisopromine Market, by Application

  • 6.1. Introduction
  • 6.2. Medical Treatments
    • 6.2.1. Chronic Pain Management
    • 6.2.2. Neuropathy Treatment
  • 6.3. Pharmaceuticals
    • 6.3.1. Over-The-Counter Drugs
    • 6.3.2. Prescription Drugs
  • 6.4. Research & Development
    • 6.4.1. Medical Studies
    • 6.4.2. Pharmaceutical Research

7. Diisopromine Market, by End User

  • 7.1. Introduction
  • 7.2. Clinics
    • 7.2.1. General Clinics
    • 7.2.2. Specialty Clinics
  • 7.3. Hospitals
    • 7.3.1. Private Hospitals
    • 7.3.2. Public Hospitals
  • 7.4. Research Institutes

8. Diisopromine Market, by Drug Form

  • 8.1. Introduction
  • 8.2. Capsules
  • 8.3. Injectables
  • 8.4. Tablets

9. Diisopromine Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Diisopromine Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Gastroenterology
    • 10.2.1. Biliary Spasm
    • 10.2.2. Irritable Bowel Syndrome
  • 10.3. Neurology
    • 10.3.1. Central Pain Syndromes
    • 10.3.2. Peripheral Neuropathy
  • 10.4. Pain Management
    • 10.4.1. Acute Pain
    • 10.4.2. Chronic Pain

11. Americas Diisopromine Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Diisopromine Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Diisopromine Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Arkema S.A.
  • 2. Asahi Kasei Corporation
  • 3. BASF SE
  • 4. Celanese Corporation
  • 5. Clariant AG
  • 6. Dow Chemical Company
  • 7. DuPont de Nemours, Inc.
  • 8. Eastman Chemical Company
  • 9. Evonik Industries AG
  • 10. Honeywell International Inc.
  • 11. Huntsman Corporation
  • 12. Lanxess AG
  • 13. LG Chem Ltd.
  • 14. LyondellBasell Industries N.V.
  • 15. Mitsui Chemicals, Inc.
  • 16. Solvay S.A.
  • 17. Sumitomo Chemical Company, Limited
  • 18. Toray Industries, Inc.
  • 19. Tosoh Corporation
  • 20. Wacker Chemie AG

LIST OF FIGURES

  • FIGURE 1. DIISOPROMINE MARKET RESEARCH PROCESS
  • FIGURE 2. DIISOPROMINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIISOPROMINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIISOPROMINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIISOPROMINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIISOPROMINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIISOPROMINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIISOPROMINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIISOPROMINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DIISOPROMINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DIISOPROMINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DIISOPROMINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DIISOPROMINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DIISOPROMINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DIISOPROMINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIISOPROMINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIISOPROMINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIISOPROMINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIISOPROMINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIISOPROMINE MARKET DYNAMICS
  • TABLE 7. GLOBAL DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIISOPROMINE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIISOPROMINE MARKET SIZE, BY NEUROPATHY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIISOPROMINE MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIISOPROMINE MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIISOPROMINE MARKET SIZE, BY MEDICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIISOPROMINE MARKET SIZE, BY PHARMACEUTICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIISOPROMINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIISOPROMINE MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIISOPROMINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIISOPROMINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIISOPROMINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIISOPROMINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIISOPROMINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIISOPROMINE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DIISOPROMINE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIISOPROMINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIISOPROMINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DIISOPROMINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DIISOPROMINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DIISOPROMINE MARKET SIZE, BY BILIARY SPASM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DIISOPROMINE MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DIISOPROMINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DIISOPROMINE MARKET SIZE, BY CENTRAL PAIN SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DIISOPROMINE MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DIISOPROMINE MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DIISOPROMINE MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS DIISOPROMINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES DIISOPROMINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC DIISOPROMINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 240. SINGAPORE DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. TAIWAN DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 264. TAIWAN DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 265. TAIWAN DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 266. TAIWAN DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 275. THAILAND DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 276. THAILAND DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 277. THAILAND DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 278. THAILAND DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 279. THAILAND DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 288. VIETNAM DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. VIETNAM DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 290. VIETNAM DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 291. VIETNAM DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 292. VIETNAM DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. VIETNAM DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA DIISOPROMINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 315. DENMARK DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 316. DENMARK DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 317. DENMARK DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 318. DENMARK DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 319. DENMARK DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 320. DENMARK DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 321. DENMARK DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 322. DENMARK DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 323. DENMARK DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 324. DENMARK DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 325. DENMARK DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 326. DENMARK DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 327. DENMARK DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 328. EGYPT DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 329. EGYPT DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 330. EGYPT DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 331. EGYPT DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 332. EGYPT DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 333. EGYPT DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 334. EGYPT DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 335. EGYPT DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 336. EGYPT DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 337. EGYPT DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 338. EGYPT DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 339. EGYPT DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 340. EGYPT DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 341. FINLAND DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 342. FINLAND DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 343. FINLAND DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 344. FINLAND DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 345. FINLAND DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 346. FINLAND DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 347. FINLAND DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 348. FINLAND DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 349. FINLAND DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 350. FINLAND DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 351. FINLAND DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 352. FINLAND DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 353. FINLAND DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 354. FRANCE DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 355. FRANCE DIISOPROMINE MARKET SIZE, BY MEDICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 356. FRANCE DIISOPROMINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 357. FRANCE DIISOPROMINE MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 358. FRANCE DIISOPROMINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 359. FRANCE DIISOPROMINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 360. FRANCE DIISOPROMINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 361. FRANCE DIISOPROMINE MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 362. FRANCE DIISOPROMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 363. FRANCE DIISOPROMINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 364. FRANCE DIISOPROMINE MARKET SIZE, BY GASTROENTEROLOGY, 2018-2030 (USD MILLION)
  • TABLE 365. FRANCE DIISOPROMINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 366. FRANCE DIISOPROMINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 367. GERMANY DIISOPROMINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 368. GERMANY DIISOPROMINE MARKET SIZE, BY